Aktis Oncology, Inc. Common stock (AKTS) - Net Assets
Based on the latest financial reports, Aktis Oncology, Inc. Common stock (AKTS) has net assets worth $-132.39 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($279.04 Million) and total liabilities ($411.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AKTS PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-132.39 Million |
| % of Total Assets | -47.45% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -311.6% |
| Growth Volatility | 10113.85 |
Aktis Oncology, Inc. Common stock - Net Assets Trend (2013–2024)
This chart illustrates how Aktis Oncology, Inc. Common stock's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see AKTS stock market capitalisation.
Annual Net Assets for Aktis Oncology, Inc. Common stock (2013–2024)
The table below shows the annual net assets of Aktis Oncology, Inc. Common stock from 2013 to 2024. Also explore net asset growth rate of Aktis Oncology, Inc. Common stock to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-87.80 Million | -53.79% |
| 2024-06-30 | $-57.09 Million | -23.30% |
| 2023-12-31 | $-46.31 Million | -153.69% |
| 2023-06-30 | $86.24 Million | +548.46% |
| 2022-12-31 | $-19.23 Million | -118.59% |
| 2022-06-30 | $103.43 Million | 0.00% |
| 2021-12-31 | $103.43 Million | -11.91% |
| 2021-06-30 | $117.41 Million | +182.95% |
| 2020-12-31 | $41.49 Million | 0.00% |
| 2020-06-30 | $41.49 Million | +59.87% |
| 2019-12-31 | $25.95 Million | 0.00% |
| 2019-06-30 | $25.95 Million | +87.40% |
| 2018-12-31 | $13.85 Million | 0.00% |
| 2018-06-30 | $13.85 Million | -7.73% |
| 2017-12-31 | $15.01 Million | 0.00% |
| 2017-06-30 | $15.01 Million | +460.87% |
| 2016-06-30 | $2.68 Million | 0.00% |
| 2015-12-31 | $2.68 Million | -36.05% |
| 2015-06-30 | $4.19 Million | 0.00% |
| 2014-12-31 | $4.19 Million | +45315.98% |
| 2014-06-30 | $9.21K | +4.79% |
| 2013-12-31 | $8.79K | 0.00% |
| 2013-06-30 | $8.79K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aktis Oncology, Inc. Common stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9283279400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $123.00K | % |
| Other Comprehensive Income | $124.00K | % |
| Other Components | $4.78 Million | % |
| Total Equity | $-87.80 Million | 100.00% |
Aktis Oncology, Inc. Common stock Competitors by Market Cap
The table below lists competitors of Aktis Oncology, Inc. Common stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
McEwen Mining Inc.
TO:MUX
|
$1.12 Billion |
|
Chengdu Galaxy Magnets
SHE:300127
|
$1.12 Billion |
|
Shandong Hi-Speed Road&Bridge
SHE:000498
|
$1.12 Billion |
|
Guangdong Shunkong Development Co Ltd
SHE:003039
|
$1.12 Billion |
|
VIEL & Cie société anonyme
PA:VIL
|
$1.12 Billion |
|
Red Star Macalline Group Corp Ltd Class A
SHG:601828
|
$1.12 Billion |
|
Leshan Giantstar Farming & Husbandry Corp Ltd
SHG:603477
|
$1.12 Billion |
|
EcoRodovias Infraestrutura e Logística S.A
SA:ECOR3
|
$1.12 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aktis Oncology, Inc. Common stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2024, total equity changed from -57,094,000 to -87,803,000, a change of -30,709,000.
- Net loss of 43,980,000 reduced equity.
- New share issuances of 185,000,000 increased equity.
- Other comprehensive income increased equity by 124,000.
- Other factors decreased equity by 171,853,000.
Equity Change Factors (2024 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-43.98 Million | -50.09% |
| Share Issuances | $185.00 Million | +210.7% |
| Other Comprehensive Income | $124.00K | +0.14% |
| Other Changes | $-171.85 Million | -195.73% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Aktis Oncology, Inc. Common stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-06-30 | $0.00 | $22.86 | x |
| 2014-12-31 | $0.33 | $22.86 | x |
| 2015-06-30 | $0.67 | $22.86 | x |
| 2015-12-31 | $0.20 | $22.86 | x |
| 2016-06-30 | $0.20 | $22.86 | x |
| 2017-06-30 | $0.88 | $22.86 | x |
| 2017-12-31 | $0.88 | $22.86 | x |
| 2018-06-30 | $0.66 | $22.86 | x |
| 2018-12-31 | $0.66 | $22.86 | x |
| 2019-06-30 | $0.94 | $22.86 | x |
| 2019-12-31 | $0.94 | $22.86 | x |
| 2020-06-30 | $1.23 | $22.86 | x |
| 2020-12-31 | $1.23 | $22.86 | x |
| 2021-06-30 | $2.70 | $22.86 | x |
| 2021-12-31 | $1.91 | $22.86 | x |
| 2022-06-30 | $1.91 | $22.86 | x |
| 2023-06-30 | $1.36 | $22.86 | x |
| 2023-12-31 | $-0.73 | $22.86 | x |
| 2024-06-30 | $-0.64 | $22.86 | x |
| 2024-12-31 | $-0.99 | $22.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aktis Oncology, Inc. Common stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2957.63%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-88.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -292.77% | 0.00% | 0.00x | 1.03x | $-27.90K |
| 2014 | -29.19% | 0.00% | 0.00x | 1.08x | $-1.64 Million |
| 2015 | -29.19% | 0.00% | 0.00x | 1.08x | $-1.64 Million |
| 2015 | -202.00% | -2121.45% | 0.06x | 1.70x | $-5.67 Million |
| 2016 | -202.00% | 0.00% | 0.00x | 1.70x | $-5.67 Million |
| 2017 | -60.68% | -53691.58% | 0.00x | 1.21x | $-10.61 Million |
| 2017 | -60.68% | -53691.58% | 0.00x | 1.21x | $-10.61 Million |
| 2018 | -156.96% | -1799.76% | 0.04x | 2.12x | $-23.12 Million |
| 2018 | -156.96% | -1799.76% | 0.04x | 2.12x | $-23.12 Million |
| 2019 | -118.97% | -2139.92% | 0.03x | 1.85x | $-33.47 Million |
| 2019 | -118.97% | -2139.92% | 0.03x | 1.85x | $-33.47 Million |
| 2020 | -98.49% | -2283.13% | 0.03x | 1.72x | $-45.02 Million |
| 2020 | -98.49% | -2283.13% | 0.03x | 1.72x | $-45.02 Million |
| 2021 | -39.96% | -708.95% | 0.05x | 1.06x | $-58.66 Million |
| 2021 | -57.23% | -385.63% | 0.10x | 1.56x | $-69.54 Million |
| 2022 | -57.23% | -385.63% | 0.10x | 1.56x | $-69.54 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.01 Million |
| 2023 | -73.70% | -234.35% | 0.18x | 1.73x | $-72.18 Million |
| 2023 | 0.00% | -105.60% | 0.22x | 0.00x | $-24.01 Million |
| 2024 | 0.00% | -613.31% | 0.39x | 0.00x | $-162.24 Million |
| 2024 | 0.00% | -2957.63% | 0.00x | 0.00x | $-35.20 Million |
Industry Comparison
This section compares Aktis Oncology, Inc. Common stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aktis Oncology, Inc. Common stock (AKTS) | $-132.39 Million | -292.77% | N/A | $1.12 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Aktis Oncology, Inc. Common stock
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatmen… Read more